Recruiting × Lymphoma, Large B-Cell, Diffuse × Clear all Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Phase 2 Recruiting
80 enrolled
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1 Recruiting
30 enrolled
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Phase 2 Recruiting
120 enrolled
MK-2140-010
Phase 3 Recruiting
1,046 enrolled
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Phase 1/2 Recruiting
30 enrolled
OPAL
Phase 1/2 Recruiting
144 enrolled
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Phase 1/2 Recruiting
20 enrolled
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Phase 2 Recruiting
43 enrolled
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
20 enrolled
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
572 enrolled
SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 Recruiting
36 enrolled
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
280 enrolled
CAN3001
Phase 3 Recruiting
700 enrolled
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Phase 1 Recruiting
32 enrolled
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Recruiting
439 enrolled
MK-9999-01A
Phase 1/2 Recruiting
90 enrolled
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1 Recruiting
18 enrolled
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Phase 2 Recruiting
32 enrolled
waveLINE-003
Phase 2/3 Recruiting
290 enrolled
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
132 enrolled
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 Recruiting
24 enrolled
GlofitReal
Recruiting
300 enrolled
Study of Out of Specification for Tisagenlecleucel
Phase 3 Recruiting
200 enrolled
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Phase 2 Recruiting
83 enrolled
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Phase 1 Recruiting
100 enrolled
MK-2140-011
Phase 2 Recruiting
594 enrolled
QUADvance
Phase 1/2 Recruiting
178 enrolled
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Phase 1/2 Recruiting
155 enrolled
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Phase 1/2 Recruiting
150 enrolled
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Phase 3 Recruiting
240 enrolled
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Phase 2 Recruiting
10 enrolled
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Phase 2 Recruiting
27 enrolled
CNS-PHLAT
Phase 2 Recruiting
36 enrolled
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
100 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Phase 2 Recruiting
35 enrolled
NexCAR19
Phase 2/3 Recruiting
40 enrolled
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
Phase 3 Recruiting
200 enrolled
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Phase 2 Recruiting
50 enrolled
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
Phase NA Recruiting
20 enrolled
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Phase 2 Recruiting
32 enrolled
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Phase 2 Recruiting
30 enrolled
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
248 enrolled
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
317 enrolled
ALPHA3
Phase 2 Recruiting
250 enrolled
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 Recruiting
24 enrolled
TC011
Phase 1/2 Recruiting
98 enrolled